In this two-part episode, Javier Bolaños-Meade, MD, with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Shernan Holtan, MD, with the University of Minnesota discuss advances and innovations in graft-versus-host disease (GVHD) prevention that call for a new standard of care in patients needing allogeneic hematopoietic cell transplantation. In Part I: PTCy and Improved Outcomes, experts highlight the history of GVHD prevention and the impacts of post-transplant cyclophosphamide (PTCy) in particular in improving outcomes and closing gaps in access to care. To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

In this two-part episode, Rachel Salit, MD, with Fred Hutch Cancer Center and Katie Schoeppner, MSW, of NMDP/Be The Match, discuss their recently developed evidence-based guidance for health care providers to assist patients in returning to work after hematopoietic cell transplantation as part of a committee of the American Society for Transplantation and Cellular Therapy (ASTCT). In Part II: Communication and Resources to Overcome Barriers, experts dive deeper into the importance of multidisciplinary collaboration and communication across the care team, as well as resources to overcome barriers and evidence-based approaches to help patients return to work. To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

In this two-part episode, Rachel Salit, MD, with Fred Hutch Cancer Center and Katie Schoeppner, MSW, of NMDP/Be The Match, discuss their recently developed evidence-based guidance for health care providers to assist patients in returning to work after hematopoietic cell transplantation as part of a committee of the American Society for Transplantation and Cellular Therapy (ASTCT). In Part I: Guidance Development and Challenges, experts explore the complex challenges transplant patients face when returning to work and major findings from their evidence-based review, including the importance of appropriate accommodations, early communication with employers, and patient-reported outcomes. To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

In this two-part episode, Zachariah DeFilipp, MD, and Andrew Brunner, MD, with Massachusetts General Hospital discuss their findings on a committee of the American Society for Transplantation and Cellular Therapy (ASTCT) to publish an evidence-based review on guidelines for the use of allogeneic hematopoietic cell transplantation in the management and treatment of myelodysplastic syndromes (MDS) from the perspective of both transplant and hematology/oncology. In Part II: Increasing Access and Shared Care, experts share insights into MDS treatment to assist both hematology/oncology practices and transplant centers in improving HCT access through shared care, especially for older patients with MDS. To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

In this two-part episode, Zachariah DeFilipp, MD, and Andrew Brunner, MD, with Massachusetts General Hospital discuss their findings on a committee of the American Society for Transplantation and Cellular Therapy (ASTCT) to publish an evidence-based review on guidelines for the use of allogeneic hematopoietic cell transplantation in the management and treatment of myelodysplastic syndromes (MDS) from the perspective of both transplant and hematology/oncology. In Part I: Risk Stratification and Eligibility, experts discuss the goals of the guidelines review, the latest research, advances in MDS risk stratification and eligibility criteria, and best practices for patients with different presentations of MDS. To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

This two-part episode features a panel discussion from Advanced Therapies Week 2023, a conference focused on advancing cell and gene therapy. In a session sponsored by Be The Match BioTherapies® and moderated by Chris McClain, MBA, Heather Stefanski, MD, PhD, Erin Leckrone, MBA, and Gabbi Giammarino, BS, discuss the current state of the cell and gene therapy industry to ramp up clinical trials and expand access to care.  In Part 2: Cost and Collaboration, experts explore cost considerations in clinical trials and what to look for in a research partner to ensure trial success. To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

This two-part episode features a panel discussion from Advanced Therapies Week 2023, a conference focused on advancing cell and gene therapy. In a session sponsored by Be The Match BioTherapies® and moderated by Chris McClain, MBA, Heather Stefanski, MD, PhD, Erin Leckrone, MBA, and Gabbi Giammarino, BS, discuss the current state of the cell and gene therapy industry to ramp up clinical trials and expand access to care.  In Part 1: Study Design and Recruitment, experts examine what’s currently happening in the industry and the biggest challenges facing clinical trial design, recruitment, and management. To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

In this two-part episode, Stephen Spellman, MBS, and Jeffrey Auletta, MD, with the National Marrow Donor Program®/Be The Match® and the CIBMTR® (Center for International Blood and Marrow Transplantation Research) discuss the current state of the science in finding an optimal donor for all patients in need of allogeneic hematopoietic cell transplantation. In Part II: Donor Optimization and Looking into the Future, experts share the opportunity to close equity gaps, optimize donor selection, and further expand access to transplant. To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

In this two-part episode, Stephen Spellman, MBS, and Jeffrey Auletta, MD, with the National Marrow Donor Program®/Be The Match® and the CIBMTR® (Center for International Blood and Marrow Transplantation Research) discuss the current state of the science in finding an optimal donor for all patients in need of allogeneic hematopoietic cell transplantation. In Part I: Donor Availability and Addressing Barriers, experts explore advances that have improved donor availability and how barriers can be addressed for patients in need of transplant. To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

In this two-part episode, Irum Khan, MD, of University of Illinois Chicago and Jonathan Moreira, MD, of Northwestern University explore novel research on the impact of structural racism on acute myeloid leukemia (AML) outcomes for underserved communities and ethnically diverse patients in the Chicago area. In Part II: Addressing Barriers and Equity Across Healthcare Teams, guests examine solutions to improve access and address barriers to care, emphasizing policy reform and the importance of strong provider relationships across the patient’s transplant journey. For more information, research and resources from this episode, or full bios of our guests, visit our site. To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

In this two-part episode, Irum Khan, MD, of University of Illinois Chicago and Jonathan Moreira, MD, of Northwestern University explore novel research on the impact of structural racism on acute myeloid leukemia (AML) outcomes for underserved communities and ethnically diverse patients in the Chicago area. In Part I: The Impact of Structural Racism on AML Outcomes, Dr. Khan shares findings from her eye-opening research and examines implications on health disparities and barriers to care for ethnically diverse patients through discussion with Dr. Moreira. For more information, research and resources from this episode, or full bios of our guests, visit our site. To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

In part two of this episode, Kelley Steffens, Dr. Woods, and Dr. Stefanski dig deeper into barriers to care and health equity concerns for adult and pediatric patients in need of HCT. They go on to discuss how building relationships, connectivity, and shared care between hematology/oncology practices and transplant centers can help, and ways to apply these principles to clinical practice.  To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

In a two-part episode on Evidence for Shared Care in HCT, our expert guests discuss recent research supporting strong relationships between hematology/oncology and transplant center care teams. Wendy Woods (formally Woods-Swafford), MD, MPH of Blank Children’s Hospital, and Heather Stefanski, MD, PhD of the National Marrow Donor Program® (NMDP)/Be The Match®, join Kelley Steffens, principal investigator and research manager at NMDP/Be The Match, to examine research findings and discuss best practices for shared or coordinated care to address access, barriers to care, and equity concerns in HCT.  To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

In this two-part episode, Karen Ballen, MD, of University of Virginia Health, and Mitul Gandhi, MD, of Virginia Cancer Specialists discuss recent research around access to HCT, as well as overcoming HCT barriers through coordinated care between transplant centers and hematology/oncology practices. In Part II: Health Equity, Solutions and Building Trust via Shared Care, they examine health disparities in access for ethnically diverse patients, propose solutions to overcome barriers for all in need of HCT, and stress the importance of shared and coordinated care between providers on the path to transplant. To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

In this two-part episode, Karen Ballen, MD, of University of Virginia Health, and Mitul Gandhi, MD, of Virginia Cancer Specialists discuss recent research around access to HCT, as well as overcoming HCT barriers through coordinated care between transplant centers and hematology/oncology practices. In Part I: Barriers in HCT and the Importance of Time, they discuss major findings from Dr. Ballen’s recent research and explore the importance of early consultation to give patients, caregivers, and providers more time to ensure optimal outcomes.  To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

This three-part episode follows a discussion of the current state of HCT by exploring its evolution over time. Fred Appelbaum, MD, of Fred Hutchinson Cancer Center, and Courtney Bellomo, MD, of New York Oncology Hematology lead the discussion. In Part 3: Persistent Misconceptions, Coordinated Care and the Future of HCT, they discuss the challenge and importance of understanding when, who, and how to refer for a transplant consultation, promoting coordinated care and open communication across the care team. They also discuss emerging advances and the future of HCT, including CAR-T and treatments for sickle cell and thalassemia. For more information, resources from the episode, or full bios of our guests, visit our site.

This three-part episode follows a discussion of the current state of HCT by exploring its evolution over time. Fred Appelbaum, MD, of Fred Hutchinson Cancer Center, and Courtney Bellomo, MD, of New York Oncology Hematology lead the discussion. In Part 2: Donor Availability, Graft Sources and the Birth of NMDP, they discuss how unrelated donor availability and alternative stem cell sources have substantially increased access to HCT. They share the story of the first unrelated donor transplant for leukemia, performed at Fred Hutch in 1979, and how it led to the development of the NMDP/Be The Match Registry.  To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

This three-part episode follows a discussion of the current state of HCT by exploring its evolution over time. Fred Appelbaum, MD, of Fred Hutchinson Cancer Center, and Courtney Bellomo, MD, of New York Oncology Hematology lead the discussion. In Part I: Transplant Then and Now, they examine what HCT looked like when they first started practicing compared to what it is today, learning alongside E. Donnall Thomas, Nobel Prize winner in HCT. Major advances in HCT and access to care are explored.  To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

Hosted by Amaro Sanchez, Be The Match Transplant Center Liaison for Latin America, our three guests will analyze, through three different cases, the outlook, progress and future challenges of transplant access for Latinx patients.

Join us as we connect with Bob Falkenberg, recipient and founder of Team Lifeblood and the Tour de TC bicycle ride. Bob started riding post-transplant to focus on wellness, he rides today to bring hope to patients undergoing transplant and to share one version of what survivorship can look like. In the second half of our podcast we’ll be joined by Be The Match subject matter experts on survivorship, Katie Shoeppner and Angela Woods. Katie and Angela know that there are as many versions of survivorship as there are patients and they will share how Be The Match is working with patients and transplant centers to explore this area of the transplant journey.